Alcon Inc.
NYSE:ALC · New York Stock Exchange
+$0.61 today
Vol 1.80M · Avg 1.91M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.4%
avg 1.1%
ROIC
3.9%
avg 1.3%
ROA
3.1%
avg 0.8%
Analysis
ROE is currently the strongest return metric at 4.4% versus its period average of 1.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David J. Endicott | Chief Executive Officer & Director | $4.07M | — | 61 | — | — |
Timothy C. Stonesifer | Senior Vice President & Chief Financial Officer | — | — | 59 | — | — |
Daniel Cravens | Vice President of Investor Relations | — | — | — | — | — |
Leon Sergio Duplan Fraustro | Senior Vice President & President of Americas | — | — | 58 | — | — |
Royce R. Bedward | Senior Vice President, General Counsel & Corporate Secretary | — | — | 60 | — | — |
Kimberly Martin | Senior VP and Chief HR & Corporate Communications | — | — | 51 | — | — |
Ian Bell | Senior Vice President & Chief Operating Officer | — | — | 55 | — | — |
Muru Murugappan | Senior Vice President and Chief Information & Transformation Officer | — | — | — | — | — |
Franck Leveiller | SVP of Global Research & Development and Chief Scientific Officer | — | — | — | — | — |
Margaret Buckley | Chief Accounting Officer | — | — | — | — | — |
Laurent Attias | Senior VP of Corporate Strategy, Business Development and Licensing (BD&L), M&A | — | — | 58 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +4.4% | +5.7% (11yr)15 analysts |
| Net Income | N/A | N/A | N/A | N/A15 analysts |
| EBIT | N/A | N/A | N/A | N/A15 analysts |
Analysis
Recent growth has been strongest in Revenue at +4.4% over three years. Forward estimates point to Revenue at +5.7% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cardinal Health, Inc.
NYSE:CAH
$52.41B
Becton, Dickinson and Company
NYSE:BDX
$52.28B
Humana Inc.
NYSE:HUM
$43.42B
Agilent Technologies, Inc.
NYSE:A
$35.99B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$28.00B
IQVIA Holdings Inc.
NYSE:IQV
$27.98B
ResMed Inc.
NYSE:RMD
$27.26B
Mettler-Toledo International Inc.
NYSE:MTD
$23.18B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.17B
Insmed Incorporated
NASDAQ:INSM
$20.60B
Who manages ALC?
Alcon Inc. (ALC) lists 11 active executives. The top listed executive is Timothy C. Stonesifer, Senior Vice President & Chief Financial Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.